<DOC>
	<DOCNO>NCT03002818</DOCNO>
	<brief_summary>This observational , prospective , open-label , single-arm , multicenter , real-life study design observe impact paritaprevir/ritonavir/ombitasvir dasabuvir regimen ( Viekirax®/Exviera® , 3D regimen ) total daytime physical activity fatigue participant Hepatitis C Virus ( HCV ) genotype 1 ( GT1 ) .</brief_summary>
	<brief_title>Quality Life Measurement Treatment Naïve Patients With HCV Genotype 1 Suffering From Fatigue Receiving Ombitasvir , Paritaprevir , Ritonavir Dasabuvir ( Viekirax®/Exviera® )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Treatmentnaïve participant Monoinfected participant chronic hepatitis C virus ( HCV ) genotype 1 ( GT1 ) Noncirrhotic participant Participants debilitate fatigue ( Fatigue Severity Scale [ FSS ] great equal 4 ) Participants source fatigue HCV ( especially , severe depression , cancer hormonal disorder cause clinically significant fatigue ) Participants condition allow adhere protocol use device investigator 's discretion Participants wheelchair dependent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ritonavir</keyword>
	<keyword>Chronic Hepatitis C ( HCV )</keyword>
	<keyword>Dasabuvir</keyword>
	<keyword>Paritaprevir</keyword>
	<keyword>Sustained Virological Response</keyword>
	<keyword>Ombitasivir</keyword>
	<keyword>Genotype 1</keyword>
</DOC>